Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 125.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,858 shares of the biotechnology company’s stock after purchasing an additional 50,640 shares during the period. Exchange Traded Concepts LLC’s holdings in Exelixis were worth $3,026,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Seizert Capital Partners LLC lifted its stake in shares of Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after buying an additional 34,875 shares during the period. Los Angeles Capital Management LLC raised its holdings in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after acquiring an additional 991,494 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after purchasing an additional 20,641 shares during the period. Tri Ri Asset Management Corp acquired a new stake in shares of Exelixis during the third quarter worth $4,396,000. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Exelixis in the third quarter valued at $577,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of research analyst reports. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. Wells Fargo & Company raised their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. HC Wainwright upped their price target on shares of Exelixis from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Truist Financial lifted their price target on shares of Exelixis from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, Guggenheim restated a “buy” rating on shares of Exelixis in a report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Exelixis Price Performance

Exelixis stock opened at $32.38 on Friday. The firm’s fifty day moving average price is $34.87 and its 200 day moving average price is $29.77. The company has a market capitalization of $9.25 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.01 and a 12-month high of $37.59.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company’s revenue was up 14.3% compared to the same quarter last year. Analysts forecast that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 96,986 shares of Exelixis stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the transaction, the executive vice president now owns 498,945 shares in the company, valued at approximately $17,463,075. This trade represents a 16.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the sale, the executive vice president now owns 288,665 shares of the company’s stock, valued at $9,918,529.40. This trade represents a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.